A systematic review and economic evaluation of pegylated liposomal doxorubicin hydrochloride for ovarian cancer

A systematic review and economic evaluation of pegylated liposomal doxorubicin hydrochloride for ovarian cancer

Bibliographic Details
Main Authors:	C. Forbes, J. Wilby, G. Richardson, M. Sculpher, L. Mather, R. Riemsma
Format:	Article
Language:	English
Published:	NIHR Journals Library 2002-01-01
Series:	Health Technology Assessment
Online Access:	https://doi.org/10.3310/hta6230

Similar Items

Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation
by: C Main, et al.
Published: (2006-03-01)

Pegylated liposomal doxorubicin in ovarian cancer
by: Robert Strother, et al.
Published: (2009-08-01)

Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation
by: Steven J Edwards, et al.
Published: (2015-01-01)

Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer
by: Zhen Yuan, et al.
Published: (2021-01-01)

Apatinib plus pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer
by: Shushant Chib, et al.
Published: (2022-01-01)

PEGylated Liposomal Doxorubicin Rechallenge following Doxorubicin-induced Pancreatitis
by: Luke Ardolino, et al.
Published: (2020-12-01)

Cardiac safety analysis of first-line chemotherapy drug pegylated liposomal doxorubicin in ovarian cancer
by: Xin-Ru Li, et al.
Published: (2022-08-01)

Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer
by: Robin L. Jones, et al.
Published: (2021-06-01)

Place of pegylated liposomal doxorubicin in the therapy of metastatic breast cancer
by: E. V. Artamonova
Published: (2016-09-01)

The impact of Pegylated liposomal doxorubicin in recurrent ovarian cancer: an updated meta-analysis of randomized clinical trials
by: Xin-Ru Li, et al.
Published: (2021-03-01)

Impact of PEGylated Liposomal Doxorubicin and Carboplatin Combination on Glioblastoma
by: Mohsen Ghaferi, et al.
Published: (2022-10-01)

Pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia
by: Joana Moreira-Barros, et al.
Published: (2018-01-01)

Long-term effect of pegylated liposomal doxorubicin in recurrent platinum-resistant ovarian cancer: а clinical case
by: I. A. Pokataev, et al.
Published: (2015-11-01)

Meta-Analysis of Trials Comparing Gemcitabine and Pegylated Liposomal Doxorubicin for Treatment in Women with Progressive or Recurrent Ovarian Cancer
by: Xia LIU, et al.
Published: (2009-12-01)

Phase 1/2 Study of Atrasentan Combined with Pegylated Liposomal Doxorubicin in Platinum-Resistant Recurrent Ovarian Cancer
by: Petronella O. Witteveen, et al.
Published: (2010-11-01)

A multicentric observational trial of pegylated liposomal doxorubicin for metastatic breast cancer
by: Wischnik Arthur, et al.
Published: (2010-01-01)

Effectiveness of a nursing support program for patients with recurrent ovarian cancer receiving pegylated liposomal doxorubicin (Caelyx®/Doxil®)
by: N. Grenier, et al.
Published: (2015-03-01)

Adipose tissue area is a predictive biomarker for the efficacy of pegylated liposomal doxorubicin in platinum‐refractory/resistant ovarian cancer
by: Hiroyuki Yoshida, et al.
Published: (2023-07-01)

Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer
by: Moore Carla L, et al.
Published: (2010-03-01)

Real-life experience using trabectedin plus pegylated liposomal doxorubicin combination to treat patients with relapsed ovarian cancer
by: Saad Tahir
Published: (2014-12-01)

Effectiveness of a nursing support program for patients with recurrent ovarian cancer receiving pegylated liposomal doxorubicin (Caelyx®/Doxil®)
by: N. Grenier, et al.
Published: (2007-07-01)

Effect of the Combination of Trabectedin and Pegylated Liposomal Doxorubicin in a BRCA2 Mutation Carrier with Recurrent Platinum-Sensitive Ovarian Cancer
by: María Jesús Rubio Pérez
Published: (2017-05-01)

Extracorporeal Elimination of Circulating Pegylated Liposomal Doxorubicin (PLD) to Enhance the Benefit of Cytostatic Therapy in Platinum-Resistant Ovarian Cancer Patients
by: Ondřej Kubeček, et al.
Published: (2015-07-01)

The role of size in PEGylated liposomal doxorubicin biodistribution and anti‐tumour activity
by: Saba Dadpour, et al.
Published: (2022-09-01)

Pegylated liposomal doxorubicin (Caelyx): contemporary aspects of its application in hematology
by: O. A. Rukavitsin, et al.
Published: (2022-11-01)

Salvage Chemotherapy in Recurrent Cervical Cancer With Biweekly Pegylated Liposomal Doxorubicin (Lipo-Dox)
by: Jen-Ruei Chen, et al.
Published: (2008-09-01)

Neoadjuvant Combination Chemotherapy with Pegylated Liposomal Doxorubicin and Vinorelbine for Locally Advanced Breast Cancer
by: Zhen-zhou SHEN, et al.
Published: (2010-02-01)

The effectiveness of liposomal doxorubicin hydrochloride in combination with cyclophosphan in the treatment of breast cancer in an experiment
by: L. A. Balykova, et al.
Published: (2021-12-01)

Biomarkers of PEGylated Liposomal Doxorubicin-Induced Hypersensitivity Reaction in Breast Cancer Patients Based on Metabolomics
by: Wei Zhuang, et al.
Published: (2022-04-01)

Pegylated Liposomal Doxorubicin Versus Epirubicin as Adjuvant Therapy for Stage I–III Breast Cancer
by: Wenxian Hu, et al.
Published: (2021-09-01)

Pegylated and liposomal doxorubicin is associated with high mortality and causes limited cardiotoxicity in mice
by: Christoffer Stark, et al.
Published: (2018-02-01)

The Way that PEGyl-DSPC Liposomal Doxorubicin Particles Penetrate into Solid Tumor Tissue
by: Xing Qing Pan, et al.
Published: (2006-01-01)

The Way that PEGyl-DSPC Liposomal Doxorubicin Particles Penetrate into Solid Tumor Tissue
by: Xing Qing Pan, et al.
Published: (2006-01-01)

Irinotecan Plus Doxorubicin Hydrochloride Liposomes for Relapsed or Refractory Wilms Tumor
by: Juan Wang, et al.
Published: (2021-09-01)

The cost implications of the use of pegylated liposomal doxorubicin when choosing an anthracycline for the treatment of platinum-resistant ovarian cancer: A low-value intervention?
by: David E. Cohn, et al.
Published: (2015-08-01)

Design and characterization of anionic PEGylated liposomal formulation loaded with paclitax for ovarian cancer
by: K Makwana, et al.
Published: (2012-01-01)

Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer
by: Francesco Schettini, et al.
Published: (2021-09-01)

Documentation of Complete Response in Metastatic Breast Cancer to Liver and Bone Achieved with Trastuzumab and Pegylated Liposomal Doxorubicin
by: Boris Kobrinsky, et al.
Published: (2008-01-01)

Lactoferrin-modified PEGylated liposomes loaded with doxorubicin for targeting delivery to hepatocellular carcinoma
by: Wei MY, et al.
Published: (2015-08-01)

Role of combination bortezomib and pegylated liposomal doxorubicin in the management of relapsed and/or refractory multiple myeloma
by: Jatin J Shah, et al.
Published: (2009-01-01)